Ingevity Corporation $NGVT Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA reduced its holdings in Ingevity Corporation (NYSE:NGVT) by 3.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 174,783 shares of the company’s stock after selling 6,740 shares during the quarter. Leeward Investments LLC MA owned 0.48% of Ingevity worth $7,531,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Ingevity by 119.1% in the 1st quarter. GAMMA Investing LLC now owns 1,137 shares of the company’s stock valued at $45,000 after acquiring an additional 618 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its position in Ingevity by 21.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 1,670 shares of the company’s stock valued at $66,000 after acquiring an additional 297 shares during the period. Empowered Funds LLC increased its position in Ingevity by 12.9% in the 1st quarter. Empowered Funds LLC now owns 5,181 shares of the company’s stock valued at $205,000 after acquiring an additional 594 shares during the period. Optimist Retirement Group LLC acquired a new stake in Ingevity in the 1st quarter valued at approximately $246,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Ingevity by 4.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 8,007 shares of the company’s stock valued at $317,000 after purchasing an additional 333 shares during the period. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NGVT has been the topic of several research analyst reports. Wall Street Zen upgraded Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. BMO Capital Markets lifted their price target on Ingevity from $62.00 to $68.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a research report on Saturday. Finally, Wells Fargo & Company lifted their price target on Ingevity from $38.00 to $48.00 and gave the company an “equal weight” rating in a research report on Monday, July 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ingevity currently has a consensus rating of “Hold” and an average price target of $58.00.

Ingevity Stock Performance

NGVT opened at $57.14 on Monday. The firm has a market cap of $2.08 billion, a PE ratio of -9.60 and a beta of 1.40. The company has a quick ratio of 0.80, a current ratio of 1.36 and a debt-to-equity ratio of 10.24. The business has a fifty day simple moving average of $56.30 and a 200-day simple moving average of $47.01. Ingevity Corporation has a fifty-two week low of $28.49 and a fifty-two week high of $60.77.

Ingevity (NYSE:NGVT) last released its quarterly earnings data on Friday, March 24th. The company reported $0.78 earnings per share for the quarter. The business had revenue of $336.00 million during the quarter. Ingevity had a positive return on equity of 84.92% and a negative net margin of 16.35%. As a group, equities analysts predict that Ingevity Corporation will post 4.45 EPS for the current fiscal year.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.